Zobrazeno 1 - 10
of 65
pro vyhledávání: '"Robert, Vitti"'
Publikováno v:
Frontiers in Public Health, Vol 12 (2024)
There is an urgent need for increased understanding of COVID-19 and strategies for its prevention, treatment, and mitigation. All participants in the research enterprise, including institutional review boards, have an ethical duty to protect particip
Externí odkaz:
https://doaj.org/article/70b54d8677434f3ca760176cc9ae5685
Autor:
Kubra Sarici, Sari Yordi, Alison Martin, Leina Lunasco, Christopher Mugnaini, Karen Chu, Hadi Moini, Robert Vitti, Sunil K. Srivastava, Justis P. Ehlers
Publikováno v:
Ophthalmology Retina. 7:543-552
Autor:
Jeffrey S. Heier, Allen C. Ho, David S. Boyer, Karl Csaky, Robert Vitti, Lorah Perlee, Karen W. Chu, Friedrich Asmus, Sergio Leal, Oliver Zeitz, Yenchieh Cheng, Thomas Schmelter, David M. Brown
Publikováno v:
Journal of VitreoRetinal Diseases. 7:8-15
Purpose: To compare intravitreal nesvacumab (anti-angiopoietin-2) + aflibercept vs intravitreal aflibercept injection (IAI) in neovascular age-related macular degeneration (nAMD). Methods: Eyes were randomized (1:2:3) to nesvacumab 3 mg + aflibercept
Autor:
Hadi Moini, Weiming Du, Rishi P Singh, Robert Vitti, Kimberly Reed, Andrea Gibson, Michael C. Singer, David A Eichenbaum
Publikováno v:
Ophthalmology. 128:1657-1660
In eyes with neovascular AMD, early persistent retinal dryness response to anti-VEGFs was associated with clinically relevant improvements in vision-related function and a greater visual acuity gain compared with when intraretinal fluid was present.
Autor:
Robert Vitti, Friedrich Asmus, Karen W. Chu, Jeffrey S. Heier, Sunil S. Patel, Sergio Leal, David M. Brown, John W. Kitchens, Thomas Schmelter, Lorah Perlee, Charles C. Wykoff, Vladimir Son, Nadia K Waheed
Publikováno v:
Ophthalmology. 127:211-220
Purpose To compare the efficacy and safety of intravitreal aflibercept + anti–platelet-derived growth factor receptor β (PDGFRβ) combination with intravitreal aflibercept injection (IAI) monotherapy in patients with treatment-naive neovascular ag
Autor:
David M, Brown, David S, Boyer, Karl, Csaky, Robert, Vitti, Lorah, Perlee, Karen W, Chu, Friedrich, Asmus, Sergio, Leal, Oliver, Zeitz, Yenchieh, Cheng, Thomas, Schmelter, Jeffrey S, Heier
Publikováno v:
Retina (Philadelphia, Pa.). 42(6)
The purpose of this study was to compare intravitreal nesvacumab (anti-angiopoietin 2) plus aflibercept with intravitreal aflibercept injection (IAI) in diabetic macular edema.The eyes (n = 302) were randomized (1:2:3) to nesvacumab 3 mg + aflibercep
Autor:
David M. Brown, Christiane Ahlers, Jean-François Korobelnik, Francesco Boscia, Paul Mitchell, Brigitte Stemper, Jeffrey S. Heier, Robert Vitti, Kay D. Rittenhouse, Frank G. Holz, Friedrich Asmus, Namrata Saroj, Nicolas Feltgen, Yuichiro Ogura
Publikováno v:
Ophthalmology Retina
Ophthalmology Retina, Elsevier, 2019, 3 (7), pp.553-560. ⟨10.1016/j.oret.2019.02.010⟩
Ophthalmology Retina, Elsevier, 2019, 3 (7), pp.553-560. ⟨10.1016/j.oret.2019.02.010⟩
International audience; PURPOSE: To evaluate the impact of baseline retinal capillary nonperfusion (RNP) and macular retinal capillary nonperfusion (MNP) status on outcomes at week 24 (W24). DESIGN: Post hoc analyses of 2 phase 3, randomized, double-
Autor:
Alyson J. Berliner, David S. Boyer, Ehsan Rahimy, Rahul N. Khurana, Karen Chu, Namrata Saroj, Andrea Gibson, W. Anthony Joseph, Robert Vitti, Yenchieh Cheng
Publikováno v:
American Journal of Ophthalmology. 200:161-168
To evaluate outcomes and disease characteristics in eyes with neovascular age-related macular degeneration that received intravitreal aflibercept injection (IAI) and ranibizumab every 12 weeks or longer (≥q12 weeks) or less than every 12 weeks (q12
Autor:
David Callanan, Michala Karkanová, Yenchieh Cheng, Karen Chu, Valerie Corp-dit-Genti, Marc D. de Smet, Jarmila Heissigerova, Yuhwen Soo, Robert Vitti, Rafael Varona, Namrata Saroj, Quan Dong Nguyen, Olga Garcia-Garcia, Sunil K. Srivastava, Erickson Kristine A, Yilmaz Ozyazgan, Ronald Buggage, P.A. Sundaram, Sibel Kadayifcilar, A. N. Athanikar
Publikováno v:
Ophthalmology. 126:428-437
Purpose To assess efficacy and safety of sarilumab, a human anti-interleukin-6 receptor antibody, for treatment of posterior segment noninfectious uveitis (NIU). Design Randomized, double-masked, placebo-controlled, phase 2 study. Participants Fifty-